Stock listing
Lang & Schwarz:A2QAR3 Achieve Life Sciences, Inc. Aktie
German listing (Lang & Schwarz) of Achieve Life Sciences, Inc. · home listing NASDAQ:ACHV
Follow Achieve Life Sciences, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:ACHV
$5.87 USD -0.05 (-0.8%)
Close on Nov 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ACHV
- Day range
- $5.61 – $5.99 USDNov 19, 2026
- Volume
- 945,707 sharesNov 19, 2026
- Market cap
- $645.9M USDAt the close on Nov 19, 2026 · price × 110.0M shares outstanding
- 52-week range
- $2.62 – $8.64 USDLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
- Traded on an average day
- $10.94M USDMedian day 1.33M shares · last 3 months, Aug 19, 2026 – Nov 11, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ACHV · Home | $5.87 USD | -0.05 (-0.8%) | 945,707 | $5.92 | $5.99 | $5.61 | $5.92 | Delayed 15+ min · 9:30 AM EST, Nov 19, 2026 |
| Frankfurt:SP4P | €5.30 EUR | -0.05 (-0.9%) | — | €5.30 | €5.30 | €5.30 | €5.35 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 19, 2026 – Nov 11, 2026 · NASDAQ:ACHV · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $6.45 | -0.33 | -4.9% | $6.54 | $6.555 | $6.29 | 1,155,289 | |
| $6.78 | +0.06 | +0.9% | $6.83 | $6.91 | $6.52 | 1,088,136 | |
| $6.72 | +0.345 | +5.4% | $6.55 | $6.75 | $6.25 | 1,074,229 | |
| $6.375 | -0.605 | -8.7% | $7.00 | $7.00 | $6.25 | 1,812,252 | |
| $6.98 | +0.25 | +3.7% | $6.87 | $7.15 | $6.81 | 1,393,672 | |
| $6.73 | +0.12 | +1.8% | $6.69 | $6.89 | $6.625 | 895,322 | |
| $6.61 | -0.22 | -3.2% | $6.89 | $6.89 | $6.33 | 1,531,845 | |
| $6.83 | -0.36 | -5.0% | $7.12 | $7.27 | $6.57 | 1,376,391 | |
| $7.19 | +0.34 | +5.0% | $6.90 | $7.23 | $6.90 | 1,374,471 | |
| $6.85 | -0.08 | -1.2% | $6.85 | $6.97 | $6.68 | 966,162 | |
| $6.93 | +0.39 | +6.0% | $6.59 | $6.94 | $6.45 | 1,486,026 | |
| $6.54 | +0.05 | +0.8% | $6.53 | $6.65 | $6.47 | 701,504 | |
| $6.49 | -0.01 | -0.2% | $6.48 | $6.61 | $6.36 | 590,135 | |
| $6.50 | -0.01 | -0.2% | $6.39 | $6.64 | $6.38 | 963,299 | |
| $6.51 | 0.00 | 0.0% | $6.50 | $6.67 | $6.38 | 2,467,797 | |
| $6.51 | -0.095 | -1.4% | $6.58 | $6.935 | $6.47 | 2,098,040 | |
| $6.605 | +0.225 | +3.5% | $6.54 | $6.735 | $6.455 | 823,013 | |
| $6.38 | -0.59 | -8.5% | $6.98 | $7.02 | $6.22 | 1,992,986 | |
| $6.97 | -0.03 | -0.4% | $7.00 | $7.13 | $6.83 | 1,197,729 | |
| $7.00 | 0.00 | 0.0% | $6.98 | $7.11 | $6.83 | 1,642,257 | |
| $7.00 | -0.06 | -0.8% | $7.00 | $7.20 | $6.92 | 1,646,100 | |
| $7.06 | -0.35 | -4.7% | $7.39 | $7.45 | $7.05 | 948,700 | |
| $7.41 | +0.22 | +3.1% | $7.20 | $7.48 | $7.14 | 987,300 | |
| $7.19 | -0.05 | -0.7% | $7.14 | $7.32 | $7.05 | 1,108,900 | |
| $7.24 | +0.21 | +3.0% | $7.02 | $7.35 | $6.96 | 1,035,900 | |
| $7.03 | +0.02 | +0.3% | $7.06 | $7.23 | $6.89 | 1,056,400 | |
| $7.01 | -0.23 | -3.2% | $7.24 | $7.34 | $6.83 | 1,702,900 | |
| $7.24 | -0.29 | -3.9% | $7.62 | $7.63 | $7.05 | 1,886,300 | |
| $7.53 | -0.56 | -6.9% | $7.89 | $8.04 | $7.52 | 1,153,300 | |
| $8.09 | +0.40 | +5.2% | $8.08 | $8.28 | $7.87 | 2,377,200 | |
| $7.69 | -0.06 | -0.8% | $7.75 | $7.76 | $7.47 | 1,027,600 | |
| $7.75 | +0.21 | +2.8% | $7.50 | $7.84 | $7.35 | 1,301,100 | |
| $7.54 | -0.29 | -3.7% | $7.90 | $7.96 | $7.51 | 1,423,000 | |
| $7.83 | 0.00 | 0.0% | $7.79 | $8.14 | $7.62 | 1,141,100 | |
| $7.83 | -0.29 | -3.6% | $8.15 | $8.20 | $7.76 | 1,328,100 | |
| $8.12 | +0.07 | +0.9% | $8.15 | $8.42 | $7.95 | 1,674,900 | |
| $8.05 | +0.07 | +0.9% | $8.03 | $8.07 | $7.82 | 1,006,800 | |
| $7.98 | +0.07 | +0.9% | $7.91 | $8.09 | $7.80 | 2,830,200 | |
| $7.91 | +0.49 | +6.6% | $7.59 | $8.11 | $7.59 | 1,871,100 | |
| $7.42 | +0.10 | +1.4% | $7.43 | $7.62 | $7.27 | 1,905,700 | |
| $7.32 | +0.09 | +1.2% | $7.22 | $7.33 | $7.02 | 1,383,900 | |
| $7.23 | +0.17 | +2.4% | $7.06 | $7.29 | $7.02 | 1,430,300 | |
| $7.06 | -0.22 | -3.0% | $7.38 | $7.44 | $7.01 | 1,460,700 | |
| $7.28 | -0.26 | -3.4% | $7.48 | $7.56 | $7.21 | 2,476,300 | |
| $7.54 | -0.30 | -3.8% | $7.82 | $7.85 | $7.52 | 2,367,200 | |
| $7.84 | -0.65 | -7.7% | $8.32 | $8.34 | $7.82 | 3,533,200 | |
| $8.49 | +0.18 | +2.2% | $8.20 | $8.56 | $8.10 | 886,400 | |
| $8.31 | -0.17 | -2.0% | $8.49 | $8.64 | $8.21 | 1,532,400 | |
| $8.48 | +0.23 | +2.8% | $8.27 | $8.52 | $8.25 | 1,044,200 | |
| $8.25 | +0.31 | +3.9% | $7.83 | $8.40 | $7.83 | 1,652,200 | |
| $7.94 | -0.16 | -2.0% | $8.07 | $8.14 | $7.82 | 1,059,000 | |
| $8.10 | -0.08 | -1.0% | $8.17 | $8.22 | $7.95 | 988,900 | |
| $8.18 | -0.09 | -1.1% | $8.31 | $8.40 | $8.16 | 987,700 | |
| $8.27 | +0.10 | +1.2% | $8.20 | $8.34 | $8.02 | 1,322,200 | |
| $8.17 | +0.23 | +2.9% | $8.04 | $8.42 | $8.01 | 1,322,400 | |
| $7.94 | -0.05 | -0.6% | $7.99 | $8.12 | $7.68 | 920,300 | |
| $7.99 | -0.03 | -0.4% | $8.11 | $8.19 | $7.90 | 1,060,700 | |
| $8.02 | -0.51 | -6.0% | $8.42 | $8.46 | $7.96 | 1,453,900 | |
| $8.53 | +1.01 | +13.4% | $7.62 | $8.61 | $7.62 | 3,924,700 |
Splits
4 splits since 2008 · NASDAQ:ACHV · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-11 | Consolidation | |
| 1-for-18 | Consolidation |
- Ticker
- Lang & Schwarz:A2QAR3
- Asset type
- Stock
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Nov 9, 2026
Achieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUIT
Latest earnings call · May 12, 2026
Achieve Life Sciences (NASDAQ:ACHV) Q1 2026 Earnings Call
Replay and transcript
Latest deck · Nov 18, 2026
Investor Presentation (2026)
Investor deck · 30 slides
Latest news
Achieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUIT
Nov 9, 2026
Closed $6.78 (+0.9%) on Nov 9, 2026
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
Nov 2, 2026
Closed $6.61 (-3.2%) on Nov 2, 2026
Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
Oct 21, 2026
Closed $6.51 (0.0%) on Oct 21, 2026
Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications
Oct 7, 2026
Closed $7.24 (+3.0%) on Oct 7, 2026
Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
Oct 1, 2026
Closed $7.53 (-6.9%) on Oct 1, 2026
Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
Sep 28, 2026
Closed $7.75 (+2.8%) on Sep 28, 2026
Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
Aug 11, 2026
Closed $6.77 (+1.5%) on Aug 11, 2026
Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality
Aug 3, 2026
Closed $6.32 (-1.6%) on Aug 3, 2026
Achieve Life Sciences Joins Russell 2000® Index
Jun 29, 2026
Closed $6.23 (+3.5%) on Jun 29, 2026
Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA
Jun 22, 2026
Closed $5.10 (+5.2%) on Jun 22, 2026
Achieve Life Sciences, Inc. on 6ix
- News releases
- 27 in the last 12 months · 179 in all · newest Nov 9, 2026 · oldest 2019
- Calls
- 25 calls with a replay · 25 with a transcript · latest May 12, 2026
- Decks
- 13 decks · latest Nov 18, 2026
Where Achieve Life Sciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ACHV · Home listing | NASDAQ | United States | USD |
| gettex:SP4P | gettex | Germany | EUR |
| Lang & Schwarz:A2QAR3 · This page | Lang & Schwarz | Germany | EUR |
| Munich:SP4P | Munich | Germany | EUR |
| BOATS:ACHV | BOATS | United States | USD |
| LS Exchange:A2QAR3 | LS Exchange | Germany | EUR |
| Tradegate:SP4P | Tradegate | Germany | EUR |
| Frankfurt:SP4P | Frankfurt | Germany | EUR |
| Stuttgart:SP4P | Stuttgart | Germany | EUR |
| Dusseldorf:SP4P | Dusseldorf | Germany | EUR |
| Hamburg:SP4P | Hamburg | Germany | EUR |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 19, 2026
- Enterprise value
- $458.4M USD
- P/E
- Loss
- EV/sales
- 4,021×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.6×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.86
Forecasts
9 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 14.58 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.34 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Andrew D. Goldberg | Chief Executive Officer & Director |
| Benjamin Halladay | Chief Financial Officer |
| Erik Atkisson | Chief Legal Officer |
| Kaitlyn Tuson | Senior Vice President, Marketing and Communications |
| Nicole Jones | VP, Strategic Communications and Stakeholder Relations |
| Mark Rubinstein | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Lucian Iancovici | Chairman of the Board of Directors |
| Aaron E. Royston | Director |
| Andrew D. Goldberg | Chief Executive Officer & Director |
| Christopher Martin | Director |
| Jeffrey Farrow | Director |
| Nancy Phelan | Director |
| Reid Waldman | Director |
| Richard Stewart | Director |
| Tom Sellig | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Achieve Life Sciences (NASDAQ:ACHV) Q1 2026 Earnings Call | Tue, May 12, 2026 · 8:30 AM ET | Replay |
| Achieve Life Sciences (NASDAQ:ACHV) Q4 2025 Earnings Call | Tue, Mar 24, 2026 · 8:30 AM ET | Replay |
| Achieve Life Sciences (NASDAQ:ACHV) Q3 2025 Earnings Call | Thu, Nov 06, 2025 · 8:30 AM ET | Replay |
| Achieve Life Sciences (NASDAQ:ACHV) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 8:30 AM ET | Replay |
| Achieve Life Sciences (NASDAQ:ACHV) Q1 2025 Earnings Call | Tue, May 13, 2025 · 8:30 AM ET | Replay |
| Achieve Life Sciences (NASDAQ:ACHV) Q4 2024 Earnings Call | Tue, Mar 11, 2025 · 8:30 AM ET | Replay |
| Achieve Life Sciences (NASDAQ:ACHV) Q3 2024 Earnings Call | Thu, Nov 07, 2024 · 4:30 PM ET | Replay |
| Achieve Life Sciences (NASDAQ:ACHV) Q2 2024 Earnings Call | Tue, Aug 13, 2024 · 4:30 PM ET | Replay |
| Achieve Life Sciences (NASDAQ:ACHV) Q1 2024 Earnings Call | Thu, May 09, 2024 · 4:30 PM ET | Replay |
| Achieve Life Sciences (NASDAQ:ACHV) Q4 2023 Earnings Call | Thu, Mar 28, 2024 · 4:30 PM ET | Replay |
All 25 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | −4.9% |
| Q2 2026 | Aug 11, 2026 · Before open | +1.5% |
| Q1 2026 | May 12, 2026 · Before open | +7.2% |
| Q4 2025 | Mar 12, 2026 | −4.8% |
| Q3 2025 | Nov 6, 2025 · Before open | −3.9% |
| Q2 2025 | Aug 7, 2025 · Before open | 0.0% |
| Q1 2025 | May 13, 2025 · Before open | +6.8% |
| Q4 2024 | Mar 26, 2025 · Before open | +2.1% |
| Q3 2024 | Nov 7, 2024 · After close | −7.4% |
| Q2 2024 | Aug 13, 2024 · After close | +0.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | +1.8% |
| Q4 2023 | Mar 13, 2024 · Before open | +1.6% |
| Q3 2023 | Nov 9, 2023 · After close | −1.9% |
| Q2 2023 | Aug 14, 2023 · After close | −3.0% |
| Q1 2023 | May 9, 2023 · After close | +12.7% |
| Q4 2022 | Mar 16, 2023 · After close | −2.0% |
| Q3 2022 | Nov 14, 2022 · After close | +5.5% |
| Q2 2022 | Aug 11, 2022 · After close | −3.9% |
| Q1 2022 | May 12, 2022 · After close | +3.9% |
| Q4 2021 | Mar 10, 2022 · Before open | −1.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (2026) | Investor deck | 30 slides | Nov 18, 2026 |
| Investor Presentation (July 2026) | Investor deck | 25 slides | July 2026 |
| Q2 2025 Earnings Presentation | Earnings | 24 slides | Aug 7, 2025 |
| Technical Presentation (May 2023) | Technical | 24 slides | May 23, 2023 |
| Technical Presentation (April 2022) | Technical | 11 slides | Apr 27, 2022 |
| IPO Roadshow (November 2020) | IPO roadshow | 32 slides | Nov 30, 2020 |
| IPO Roadshow (December 2019) | IPO roadshow | 39 slides | Dec 2, 2019 |
| Technical Presentation (September 2019) | Technical | 38 slides | Sep 13, 2019 |
| IPO Roadshow (June 2018) | IPO roadshow | 36 slides | Jun 6, 2018 |
| Corporate Update (February 2018) | Corporate update | 11 slides | Feb 20, 2018 |
All 13 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Oncogenex Pharmaceuticals — Merger or Acquisition (June 2017) | Merger or acquisition | 33 slides | Jun 13, 2017 |
| Oncogenex Pharmaceuticals — Merger or Acquisition (January 2017) | Merger or acquisition | 26 slides | Jan 6, 2017 |
| OncoGenex Pharmaceuticals — FY2008 Earnings Presentation | Earnings | 26 slides | Mar 11, 2009 |
Financings
| Raise | Date |
|---|---|
| Private placement of securities and milestone warrants Update: US$180M–US$354M Use of proceeds: Development and launch of cytisinicline, if approved, for nicotine dependence | Apr 16, 2026 |
| Public offering of common stock and accompanying common warrants Closed: US$45M raised · US$3 a share · Warrants at US$3 for 60 months · Citizens Capital Markets +2 Dealers: Citizens Capital Markets (co-lead), Raymond James (co-lead), Lake Street Capital Markets, LLC Use of proceeds: Advance cytisinicline through potential FDA marketing approval, plus working capital and general corporate purposes | Jun 30, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.06M |
| Cost of revenue | 228.0K | 229.0K | 228.0K | 236.0K | 250.0K | 255.0K | 254.0K | 282.0K | 282.0K | 0 |
| Gross profit | -228.0K | -229.0K | -228.0K | -236.0K | -250.0K | -255.0K | -254.0K | -282.0K | -282.0K | 5.06M |
| Research and development | 23.0M | 22.8M | 15.8M | 30.1M | 24.0M | 6.88M | 9.67M | 5.87M | 3.10M | 286.0K |
| Selling, general and administrative | 31.9M | 16.3M | 11.4M | 10.7M | 9.13M | 7.87M | 6.85M | 6.95M | 3.53M | 8.93M |
| Operating income | -54.9M | -39.1M | -27.3M | -40.8M | -33.1M | -14.8M | -16.5M | -12.8M | -6.63M | -21.2M |
| Depreciation and amortization | 228.0K | 229.0K | 228.0K | 236.0K | 250.0K | 255.0K | 31.0K | 60.0K | 59.0K | 188.0K |
| EBITDA | -54.7M | -38.8M | -27.0M | -40.6M | -32.8M | -14.5M | -16.5M | -12.8M | -6.57M | -21.0M |
| Interest expense | 819.0K | 2.18M | 2.85M | 1.79M | 17.0K | 69.0K | 0 | 0 | 0 | 0 |
| Income before tax | -54.6M | -39.8M | -29.8M | -42.4M | -33.2M | -14.7M | -16.4M | -12.7M | -13.6M | -1.74M |
| Income tax | -39.8M | -475.0K | -250.0K | -69.0K | -254.0K | -126.0K | -3.05M | 0 | ||
| Net income | -54.6M | -39.8M | -29.8M | -42.4M | -33.2M | -14.7M | -16.4M | -12.7M | -10.6M | -1.23M |
| Earnings per share, basic | -1.25 | -1.24 | -1.50 | -4.00 | -4.08 | -5.42 | -39.76 | -72.29 | -22.07 | -581.25 |
| Earnings per share, diluted | -1.25 | -1.24 | -1.50 | -4.00 | -4.08 | -5.42 | -39.76 | -72.29 | -22.07 | -581.25 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 20.9M | 12.8M | 15.5M | 24.8M | 43.0M | 35.9M | 16.7M | 9.52M | 5.28M | 15.0K |
| Short-term investments | 15.5M | 21.6M | 0 | 50.0K | 5.09M | 222.0K | 10.2M | |||
| Receivables | 111.0K | 105.0K | 153.0K | 8.00K | 7.00K | 9.00K | 478.0K | |||
| Inventory | -2.49M | -8.00K | -50.0K | 222.0K | 0 | |||||
| Current assets | 39.9M | 36.5M | 17.0M | 27.3M | 44.6M | 37.0M | 17.3M | 15.5M | 5.91M | 18.0K |
| Property, plant and equipment | 3.00K | 8.00K | 13.0K | 4.00K | 15.0K | 42.0K | 57.0K | 35.0K | 59.0K | 258.0K |
| Goodwill | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M |
| Total assets | 41.8M | 38.6M | 19.4M | 30.0M | 47.5M | 40.3M | 21.1M | 19.1M | 9.89M | 3.81M |
| Accounts payable | 867.0K | 1.95M | 618.0K | 1.66M | 841.0K | 332.0K | 859.0K | 144.0K | 213.0K | 95.0K |
| Current liabilities | 9.08M | 6.68M | 20.8M | 21.6M | 4.55M | 2.94M | 2.87M | 3.27M | 2.01M | 3.07M |
| Long-term debt | 11.2M | 9.84M | 16.1M | 14.9M | 0 | 49.0K | ||||
| Total debt | 15.0M | 9.96M | 16.7M | 16.2M | 15.0M | 169.0K | 362.0K | 35.0K | 27.0K | 106.0K |
| Total liabilities | 20.3M | 17.7M | 20.8M | 21.7M | 19.5M | 3.01M | 3.03M | 3.28M | 2.01M | 3.20M |
| Shareholders' equity | 21.5M | 20.9M | -1.45M | 8.30M | 28.0M | 37.3M | 18.1M | 15.8M | 15.8M | 610.0K |
| Shares outstanding | 53.2M | 34.7M | 21.2M | 17.9M | 9.45M | 6.11M | 1.47M | 6.72M | 1.19M | 21.2K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -49.5M | -29.8M | -24.5M | -37.6M | -29.4M | -13.5M | -15.2M | -10.6M | -9.11M | -202.0K |
| Capital spending | -3.00K | 0 | -21.0K | 0 | -17.0K | -17.0K | -53.0K | -46.0K | -46.0K | -46.0K |
| Free cash flow | -49.5M | -29.8M | -24.5M | -37.6M | -29.4M | -13.5M | -15.3M | -10.7M | -9.11M | -248.0K |
| Cash from investing | 6.11M | -21.6M | -21.0K | -17.0K | -17.0K | 5.04M | -5.13M | 12.6M | 10.6M | |
| Cash from financing | 51.5M | 48.5M | 15.3M | 19.3M | 36.6M | 32.7M | 17.3M | 19.8M | 2.00M | 150.0K |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | 0 | 0 | -30.0K | -47 | 32.7M | 4.99M | 14.8M | -5 | 0 | |
| Change in cash | 8.18M | -2.82M | -9.22M | -18.3M | 7.17M | 19.2M | 7.15M | 4.01M | 5.54M | -52.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 1, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 14, 2026 | Current report | SEC |
| 424B5 · Prospectus | Aug 14, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 28, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 27, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 8, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 6, 2026 | Meeting outcome | SEC |
| ARS · Annual report to shareholders | Jun 8, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Jun 8, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 2, 2026 | Management or board change | SEC |
| PRE 14A · Preliminary proxy statement | May 29, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | May 22, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 19, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 13, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 12, 2026 | Offer document | SEC |
| S-3 · Registration statement | May 12, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 7, 2026 | Big-stake notice | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2026 | Annual report | SEC |
| SCHEDULE 13D · Big-stake notice | Apr 27, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Apr 27, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 24, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Apr 24, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Apr 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 24, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 24, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 24, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 16, 2026 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Apr 16, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 24, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 24, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 24, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jan 30, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 29, 2026 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Jan 27, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 27, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jan 23, 2026 | Offer document | SEC |
| 3 · Initial statement of ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 3 · Initial statement of ownership | Oct 21, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 7, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 19, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 11, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Sep 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 5, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 27, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jun 27, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Jun 26, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 6, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 9, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 30, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 11, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 11, 2025 | Results | SEC |
| 8-K · Current report | Feb 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 14, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 14, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jan 10, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 10, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 9, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 9, 2024 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Dec 5, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 19, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Nov 15, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 14, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 14, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| S-3 · Registration statement | Nov 7, 2024 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Nov 7, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 4, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 31, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 25, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Oct 25, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 27, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Sep 27, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 26, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 8-K · Current report | Jul 29, 2024 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Jul 9, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 3, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 3, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jun 28, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 27, 2024 | Current report | SEC |
| 8-K · Current report | Jun 6, 2024 | Meeting outcome | SEC |
| SC 13G/A · Big-stake notice, amended | May 20, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | May 17, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| EFFECT · Notice that a registration is effective | May 7, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 2, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 2, 2024 | Other filings | SEC |
| S-3 · Registration statement | Apr 26, 2024 | Offer document | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 23, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 28, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Mar 11, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 29, 2024 | Results | SEC |
| 424B5 · Prospectus | Feb 29, 2024 | Offer document | SEC |
| SC 13G · Big-stake notice | Feb 27, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 11, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2023 | Results | SEC |
This page holds 200 of 1,001 filings. Open Filings
Cap table
Built by 6ix from Achieve Life Sciences, Inc.’s releases · as of Jun 30, 2025
- Common shares
- 110,034,457
- Fully diluted
- 110,034,457
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 110,034,457 |
Warrants and options
| Lot |
|---|
| Warrants · US$3.00 · expire about Jun 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 110,034,457 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jeffrey Farrow Other companies: Tarsus Pharmaceuticals, Inc. (See Remarks · Since at least Apr 24, 2023); Lisata Therapeutics, Inc. (Director · Since Oct 13, 2026 · Appointed, no departure found); Global Blood Therapeutics Inc (Chief Financial Officer · Apr 4, 2016 – Oct 5, 2022 · Past); ZS Pharma Inc (Chief Financial Officer · Jul 8, 2015 – Dec 17, 2015 · Past); Hyperion Therapeutics Inc (CFO · Jul 25, 2012 – May 7, 2015 · Past); Renovis Inc (V.P., Finance and CAO · Jul 1, 2007 – May 2, 2008 · Past) | Director · Since at least May 29, 2026 |
| Bridget Martell Other companies: Delcath Systems, Inc. (Director · Since at least May 23, 2024); Aligos Therapeutics, Inc. (Director · Since at least Nov 16, 2021); Ayala Pharmaceuticals Inc (Director · Oct 18, 2023 – Oct 18, 2023 · Past); POINT Biopharma Global Inc (Director · Jun 12, 2023 – Jun 13, 2023 · Past); Kura Oncology, Inc. (Acting Chief Medical Officer · Feb 10, 2020 – Aug 24, 2020 · Past) | Director · Since at least Mar 15, 2021 |
| Donald Joseph Other companies: Acer Therapeutics Inc (See Remarks · Apr 16, 2018 – Nov 17, 2023 · Past); Humanigen Inc (Chief Legal Officer · Jul 30, 2013 – Feb 16, 2015 · Past); Renovis Inc (SVP, Gen. Counsel & Secretary · May 16, 2006 – Jan 3, 2007 · Past); Abgenix Inc (Senior VP, Gen. Counsel & Sec. · Apr 1, 2006 – Apr 1, 2006 · Past) | Director · Aug 1, 2017 – May 31, 2022 · Past |
| H Stewart Parker Other companies: Codexis, Inc. (Director · Since at least Dec 16, 2022); Sangamo Therapeutics, Inc. (Director · Since at least Jun 17, 2014); Impel Neuropharma Inc (Director · Apr 22, 2021 – Jul 11, 2021 · Past); Armata Pharmaceuticals, Inc. (Director · Jun 12, 2006 – May 22, 2019 · Past) | Director · Mar 23, 2010 – May 12, 2020 · Past |
| Jay M. Moyes Other companies: SiNtx Technologies, Inc. (Audit Committee Chair · Since at least Apr 3, 2025); Puma Biotechnology Inc (Director · Since at least Jun 14, 2022); BioCardia, Inc. (Director · Since at least Jun 10, 2022); Sera Prognostics, Inc. (Chief Financial Officer · Mar 6, 2023 – Jun 7, 2023 · Past) | Director · May 31, 2022 – May 31, 2022 · Past |
| Lucian Iancovici Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Rallybio Corporation (Board Member · Since at least Jul 29, 2021); CeriBell, Inc. (Director · Oct 10, 2024 – Oct 10, 2024 · Past) | Chairman of the Board of Directors · Since at least Apr 17, 2026 |
| Mark Oki Other companies: Aytu BioPharma, Inc. (Chief Financial Officer · Jan 17, 2022 – Aug 11, 2023 · Past); VIVUS Inc (Chief Financial Officer & CAO · Oct 19, 2015 – Jan 29, 2020 · Past); Alexza Pharmaceuticals Inc (Former SVP, CFO, Secretary · May 18, 2010 – Oct 16, 2015 · Past) | Chief Financial Officer · Since at least Dec 5, 2024 |
| Stuart Duty Other companies: Foghorn Therapeutics Inc. (Director · Since at least May 1, 2025); Milestone Pharmaceuticals Inc. (Independent Non-Executive Director · Since at least Jul 15, 2024); EyePoint, Inc. (Board Member · Since at least Oct 16, 2023) | Director · Since at least Mar 29, 2023 |
| Christopher Martin Other companies: Oruka Therapeutics, Inc. (Director · Since at least Dec 11, 2025); Edgewise Therapeutics, Inc. (Director · Since at least Nov 19, 2025) | Director · Since at least May 11, 2026 |
| Erik Atkisson Other companies: Rain Oncology Inc (General Counsel and CCO · Mar 2, 2023 – Jan 26, 2024 · Past); Eiger Biopharmaceuticals Inc (GC & Chief Compliance Officer · Sep 22, 2021 – Jan 26, 2023 · Past) | Chief Legal Officer · Since at least Oct 20, 2025 |
All 32 people
| Person | Seat |
|---|---|
| George W Dunbar Jr Other companies: Capricor Therapeutics, Inc. (Director · Since at least Nov 20, 2013); Vericel Corporation (Director · Jul 17, 2006 – Mar 11, 2010 · Past) | Director · May 9, 2006 – May 10, 2007 · Past |
| John Bencich Other companies: AEON Biopharma, Inc. (Chief Financial Officer - · Since at least Apr 1, 2026); Trubion Pharmaceuticals Inc (V.P. and CFO · Nov 16, 2009 – Oct 28, 2010 · Past) | CEO, Director · Aug 11, 2014 – Aug 16, 2024 · Past |
| Andrew D. Goldberg Other companies: Tarsus Pharmaceuticals, Inc. (Director · Since at least Dec 15, 2023) | CEO and President, Director · Since at least Apr 18, 2026 |
| Cameron William Lawrence Other companies: GNC Holdings Inc (SVP Finance, CAO · Apr 15, 2019 – Mar 25, 2020 · Past) | Principal Accounting Officer · Feb 24, 2010 – May 8, 2012 · Past |
| Dwight Winstead Other companies: CareFusion Corp (Chief Operating Officer · Jul 28, 2009 – Dec 7, 2010 · Past) | Director · May 9, 2006 – May 13, 2010 · Past |
| Reid Waldman Other companies: Veradermics, Incorporated (Chief Executive Officer, Director · Since at least Feb 3, 2026) | Director · Since at least May 29, 2026 |
| Thomas Braxton King Other companies: TFF Pharmaceuticals Inc (Director · Dec 11, 2023 – Jul 3, 2024 · Past) | Director · Since at least Jan 22, 2024 |
| Aaron E. Royston | Director · Since at least Apr 16, 2026 |
| Benjamin Halladay | Chief Financial Officer · Since Oct 5, 2026 |
| Cindy Jacobs | President & CMO · Since at least Aug 21, 2008 |
| Craig Donnelly | Chief Operations Officer · Since at least Jan 28, 2025 |
| Jaime Xinos | Chief Commercial Officer · Since at least Oct 15, 2024 |
| Kaitlyn Tuson | Senior Vice President, Marketing and Communications · Since at least Oct 7, 2026 |
| Kristen B Slaoui | Director · Since at least Jan 6, 2025 |
| Mark Rubinstein | Chief Medical Officer · Since at least Jan 28, 2025 |
| Martin A Mattingly | Director · May 11, 2021 – May 31, 2022 · Past |
| Nancy Phelan | Director · Since at least Mar 11, 2025 |
| Nicole Jones | VP, Strategic Communications and Stakeholder Relations · Since at least Nov 2, 2026 |
| Richard Stewart | Director · Since at least Jan 22, 2024 |
| Scott Daniel Cormack | Director · Aug 21, 2008 – May 12, 2020 · Past |
| Thomas Sellig | Director · Since at least Mar 29, 2023 |
| Tom Sellig | Director · Since at least Apr 15, 2026 |
Log in to ask 6ix AI your own questions about Achieve Life Sciences, Inc.